Andreassen K V, Feigh M, Hjuler ST, Gydesen S, Henriksen JE, Beck-Nielsen H, Christiansen C, Karsdal M a, and Henriksen K (2014) A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats. Am J Physiol Endocrinol Metab 307:E24-33.
Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, and Weyer C (2007) Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: A phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 92:2977–2983.
Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean MEJ, Niskanen L, Rasmussen MF, Rissanen A, Rossner S, Savolainen MJ, and Van Gaal L (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36:843–854, England.
Bello NT, Kemm MH, Ofeldt EM, and Moran TH (2010) Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. Am J Physiol Integr Comp Physiol 299:R945–R952.
Crane J, and McGowan B (2016) The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis 7:92–107.
Cusi K (2009) Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis. Clin Liver Dis 13:545–563.
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, Andreasen AH, Jensen CB, and DeFronzo RA (2015) Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 314:687–699, United States.
Duffy S, Lutz TA, and Boyle CN (2018) Rodent models of leptin receptor deficiency are less sensitive to amylin. Am J Physiol Regul Integr Comp Physiol 315: R856-R865
Flint A, Kapitza C, Hindsberger C, and Zdravkovic M (2011) The once-daily human Glucagon-Like Peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 28:213–226.
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham L, and Anis AH (2009) The incidence of co-morbidities related to obesity and overweight : A systematic review and meta-analysis. 20:1–20.
Gydesen S, Hjuler ST, Freving Z, Andreassen KV, Sonne N, Hellgren LI, Karsdal MA, and Henriksen K (2017) A novel Dual Amylin and Calcitonin Receptor Agonist (DACRA), KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol, doi: 10.1111/bph.13723.
Gydesen S, Andreassen KV, Hjuler ST, Christensen JM, Karsdal MA, and Henriksen K (2016) KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight. Am J Physiol Endocrinol Metab ajpendo.00514.2015.
Gydesen S, Andreassen KV, Hjuler ST, Hellgren LI, Karsdal MA, and Henriksen K (2017) Optimization of Tolerability and Efficacy of Dual Amylin and Calcitonin Receptor Agonist, KBP-089, through Dose Escalation and Combination with a GLP-1 Analogue. Am J Physiol - Endocrinol Metab ajpendo.00419.2016.
Haslam DW, and James WPT (2005) Obesity. Lancet (London, England) 366:1197–1209, England.
Hjuler ST, Gydesen S, Andreassen KV, Lund S, Pedersen K, Hellgren LI, Karsdal MA, and Henriksen K (2016) The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Increases Insulin Sensitivity and Induces Weight Loss in Rats with Obesity. Obesity 24:1712–1722.
Hjuler ST, Andreassen K V, Gydesen S, Karsdal MA, and Henriksen K (2015) KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration. Eur J Pharmacol 762:229–238.
Hjuler ST, Gydesen S, Andreassen KV, Karsdal MA, and Henriksen K (2017) The Dual Amylin- and Calcitonin Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 Diabetes. J Pharmacol Exp Ther 362: 24-30.
Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, and Chapman IM (2012) Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 97:258–266, Elsevier Ireland Ltd.
Jansson JO, and Palsdottir V (2015) Brain IL-6 - Where amylin and GLP-1 antiobesity signaling congregate. Diabetes 64:1498–1499.
Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, and Bjerre Knudsen L (2012) Liraglutide: Short-lived effect on gastric emptying-long lasting effects on body weight. Diabetes, Obes Metab 14:531–538.
Kahn SE, Hull RL, and Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846.
Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, and Hayes MR (2012) The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 62:1916–1927, Elsevier Ltd.
Klein DJ, Battelino T, Chatterjee DJ, Jacobsen L V., Hale PM, and Arslanian S (2014) Liraglutide’s Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Technol Ther 16:679–687.
Knudsen LB (2010) Liraglutide: The therapeutic promise from animal models. Int J Clin Pract 64:4–11, Blackwell Publishing Ltd.
Ladenheim EE (2015) Liraglutide and obesity: A review of the data so far. Drug Des Devel Ther 9:1867–1875.
Lean MEJ, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L, and Astrup A (2014) Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes 38:689–697.
Liberini CG, Koch-Laskowski K, Shaulson E, McGrath LE, Lipsky RK, Lhamo R, Ghidewon M, Ling T, Stein LM, Hayes MR (2019). Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss. Sci Rep 9: 8447
Mack CM, Smith PA, Athanacio JR, Xu K, Wilson JK, Reynolds JM, Jodka CM, Lu MGW, and Parkes D. (2011) Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. Diabetes,Obesity Metab 1105–1113.
Mack CM, Soares CJ, Wilson JK, Athanacio JR, Turek VF, Trevaskis JL, Roth JD, Smith PA, Gedulin B, Jodka CM, Roland BL, Adams SH, Lwin A, Herich J, Laugero KD, Vu C, Pittner R, and Jr JRP (2010) Davalintide ( AC2307 ), a novel amylin-mimetic peptide : enhanced pharmacological properties over native amylin to reduce food intake and body weight. 385–395.
Mack C, Wilson J, Athanacio J, Reynolds J, Laugero K, Guss S, Vu C, Roth J, Parkes D (2007) Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol 293:R1855-R1863.
Milić S, Lulić D, and Štimac D (2014) Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J Gastroenterol 20:9330–9337.
Pories WJ (2008) Bariatric surgery: risks and rewards. J Clin Endocrinol Metab 93:S89-96, United States.
Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, and Kolterman OG (2004) Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus : a 1-year , randomized controlled trial. Diabet Med 21:1204–1212.
Raun K, Von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, and Knudsen LB (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56:8–15.
Roth JD, Erickson MR, Chen S, and Parkes DG (2012) GLP-1R and amylin agonism in metabolic disease: Complementary mechanisms and future opportunities. Br J Pharmacol 166:121–136.
Ryan G, Briscoe TA, and Jobe L (2009) Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther 2:203–14.
Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, and Weyer C (2008) Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 31:1816–23.
Van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, and Saris WHM (2014) Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes 38:784–793.
Vilsbøll T, Brock B, Perrild H, Levin K, Lervang H, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, and Madsbad S (2008) Original Article : Treatment Liraglutide , a once-daily human GLP-1 analogue , improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 152–156.
Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges J-P, Verhoeven R, Buganova I, and Madsbad S (2007) Liraglutide , a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes. Diabetes Care 1608–10.
Weyer C, Maggs DG, Young AA, and Kolterman OG (2001) Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Curr Pharm Des 7:1353–1373.
Wielinga PY, Lowenstein C, Muff S, Munz M, Woods SC, Lutz TA (2010) Central amylin acts as an adiposity signal to control body weight and energy expenditure. Physiol Behav 101:45-52